Related Experiment Video

Updated: Nov 1, 2025

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.4K

Stathmin dynamics modulate the activity of eribulin in breast cancer cells

Mikihiro Yoshie1, Akari Ishida1, Haruka Ohashi1

  • 1Department of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan.

Pharmacology Research & Perspectives
|June 27, 2021
PubMed

Insights

Stathmin phosphorylation influences eribulin

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Stathmin, a microtubule-regulating phosphoprotein, is highly expressed in breast cancer.
  • Eribulin is a microtubule-depolymerizing agent used for advanced breast cancer treatment.
  • The precise mechanisms of eribulin's action and its interaction with stathmin are not fully understood.

Purpose of the Study:

  • To investigate stathmin's role in eribulin's antiproliferative activity in breast cancer cells.
  • To elucidate the signaling pathways regulating stathmin phosphorylation in response to eribulin.

Main Methods:

  • Investigated eribulin's effect on stathmin phosphorylation in MCF7 and MDA-MB-231 cells.
  • Utilized protein kinase A (H89) and Ca2+/calmodulin-dependent kinase II (KN62) inhibitors.
  • Examined the impact of protein phosphatase 2A (PP2A) activators (FTY720) and inhibitors (okadaic acid) on stathmin phosphorylation.
  • Assessed the effect of eribulin on PP2A subunit expression and activity.
  • Compared eribulin's antiproliferative effects in stathmin-overexpressing versus control cells.

Main Results:

  • Eribulin induced stathmin phosphorylation, which was modulated by protein kinase A and Ca2+/calmodulin-dependent kinase II.
  • Phosphorylated stathmin levels were decreased by PP2A activation and increased by PP2A inhibition.
  • Eribulin treatment led to decreased expression of PP2A subunits.
  • The antiproliferative effect of eribulin was enhanced in cells overexpressing stathmin.

Conclusions:

  • Stathmin phosphorylation dynamics are closely linked to eribulin's antiproliferative effects in breast cancer.
  • Stathmin may serve as a predictive biomarker for eribulin's therapeutic efficacy in breast cancer patients.
Keywords:
breast cancer cellseribulinmicrotubulestathmin

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.4K

Related Concept Videos

Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K